Genetic and serological markers to identify phenotypic subgroups in a Dutch Crohn' s disease population
R K Linskens1, R C Mallant-Hent, L S Murillo
1Department of Gastroenterology, VU Medical Center, Amsterdam, The Netherlands. r.linskens@st-anna.nl
Insights
Genetic mutations and antibodies are key to understanding Crohn's disease. CARD15 mutations and specific antibodies correlate with disease behavior, aiding in patient subgroup identification and prognosis.
Area of Science:
- Gastroenterology
- Genetics
- Immunology
Background:
- Crohn's disease pathogenesis involves genetic and microbial factors.
- CARD15 mutations may link host genetics and gut microbiota, influencing immune responses.
- Specific antibodies like anti-Saccharomyces cerevisiae antibody (ASCA) and perinuclear anti-neutrophil cytoplasmic antibodies (p-ANCA) are associated with Crohn's disease.
Purpose of the Study:
- To investigate the incidence of CARD15 mutations (3020insC and 2722G>C), ASCA, and p-ANCA in Crohn's disease patients.
- To correlate these genetic and serological markers with disease phenotype according to the Vienna classification.
Main Methods:
- Study included 108 Crohn's disease patients with a mean disease duration of 16 years.
- Incidence of two CARD15 mutations, ASCA, and p-ANCA was assessed.
- Phenotype was analyzed using the Vienna classification.
Main Results:
- CARD15 frameshift mutation prevalence was 21%. ASCA positivity was 62%, and p-ANCA positivity was 9%.
- Prevalence of ASCA and p-ANCA was higher in CARD15 mutation carriers.
- CARD15 mutation carriers with ASCA positivity predominantly had ileal disease. Mutation carriership associated with penetrating and stricturing disease behavior. ASCA associated with ileal involvement, and p-ANCA with ulcerative-like colonic disease.
Conclusions:
- Genetic (CARD15) and serological (ASCA, p-ANCA) markers can help define Crohn's disease patient subgroups.
- These markers may improve prediction of disease behavior, prognosis, and therapeutic strategies.
Background And Aims:
Both genetic and microbial factors seem to play a pivotal role in the aetiopathogenesis of Crohn's disease. The CARD15 frameshift mutation might link host genetic factors and the indigenous microbial flora, since CARD15 expression is stimulated by peptidoglycan, thereby activating NF-kappaB. It is hypothesised that CARD15 mutation carriers have defective anti-microbial reactions, resulting in more penetrating lesions and antibody responses, which are now being used as highly specific markers for Crohn's disease. The serological marker anti-Saccharomyces cerevisiae antibody directed against cell wall oligomannosidic epitopes has high specificity for Crohn's disease. Perinuclear anti-neutrophil cytoplasmic antibodies have been found in a subgroup of Crohn's disease patients, mostly with colonic involvement.
Methods:
We investigated the incidence of two CARD15 mutations (3020insC and 2722G>C), anti-S. cerevisiae antibody, and perinuclear anti-neutrophil cytoplasmic antibody in 108 (73F/35M) patients with Crohn's disease with a mean duration of disease since diagnosis of 16 (1-41) years in relation to their phenotype, according to the Vienna classification.
Results:
The prevalence of CARD15 frameshift mutation was 21%. Of all patients, 62% were anti-S. cerevisiae antibody positive, and 9% had perinuclear anti-neutrophil cytoplasmic antibodies. The prevalence of both anti-S. cerevisiae antibodies and perinuclear anti-neutrophil cytoplasmic antibodies was higher in the mutation carriers compared to non-carriers. Remarkably, all patients with a CARD15 mutation and positive anti-S. cerevisiae antibody had ileal disease. Carriership of the mutation was significantly associated with penetrating behaviour of the disease and weakly associated with stricturing behaviour. Furthermore, anti-S. cerevisiae antibody was associated with ileal disease involvement. Finally, most perinuclear anti-neutrophil cytoplasmic antibody positive patients showed ulcerative-like behaviour of disease (by means of colonic localisation).
Conclusions:
Genetic and serologic markers might be useful in defining patient subgroups. This may result in a more accurate prediction of disease behaviour, prognosis and therapeutic approach.
Related Concept Videos
01:25Inflammatory Bowel Disease III: Crohn's Disease
01:11Genome-wide Association Studies-GWAS
GWAS does not require the identification of the target gene involved in...
01:29Pharmacogenomics: Identification of New Drug Targets
01:30Inflammatory Bowel Disease II: Crohn's Disease
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by transmural...